Literature DB >> 18599167

Cost effectiveness of rabies post exposure prophylaxis in the United States.

Praveen Dhankhar1, Sagar A Vaidya, Daniel B Fishbien, Martin I Meltzer.   

Abstract

There is growing concern in the United States about the excessive use of rabies post exposure prophylaxis (PEP) treatment. In this paper we have estimated the cost effectiveness of rabies PEP treatment under various scenarios of rabies transmission. When the risk of a patient getting rabies is deemed greater than 0.7%, then giving PEP will be cost saving (societal perspective). For lower risks of transmission, cost effectiveness estimates ranged from approximately $500,000 per life saved to $billions. The uncertainty caused by the wide range of cost effectiveness can only be resolved through analysis of data describing rabies transmission risk in a variety of scenarios.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599167     DOI: 10.1016/j.vaccine.2008.05.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Imported episodic rabies increases patient demand for and physician delivery of antirabies prophylaxis.

Authors:  Zélie Lardon; Laurence Watier; Audrey Brunet; Claire Bernède; Maryvonne Goudal; Laurent Dacheux; Yolande Rotivel; Didier Guillemot; Hervé Bourhy
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

2.  Estimating the risk of rabies transmission to humans in the U.S.: a Delphi analysis.

Authors:  Sagar A Vaidya; Susan E Manning; Praveen Dhankhar; Martin I Meltzer; Charles Rupprecht; Harry F Hull; Daniel B Fishbein
Journal:  BMC Public Health       Date:  2010-05-26       Impact factor: 3.295

3.  Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania.

Authors:  Eunha Shim; Katie Hampson; Sarah Cleaveland; Alison P Galvani
Journal:  Vaccine       Date:  2009-11-27       Impact factor: 3.641

4.  Expression of rabies virus G protein in carrots (Daucus carota).

Authors:  Edith Rojas-Anaya; Elizabeth Loza-Rubio; Maria Teresa Olivera-Flores; Miguel Gomez-Lim
Journal:  Transgenic Res       Date:  2009-05-29       Impact factor: 2.788

5.  A one health framework for the evaluation of rabies control programmes: a case study from Colombo City, Sri Lanka.

Authors:  Barbara Häsler; Elly Hiby; Will Gilbert; Nalinika Obeyesekere; Houda Bennani; Jonathan Rushton
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

6.  DVT surveillance program in the ICU: analysis of cost-effectiveness.

Authors:  Ajai K Malhotra; Stephanie R Goldberg; Laura McLay; Nancy R Martin; Luke G Wolfe; Mark M Levy; Vishal Khiatani; Todd C Borchers; Therese M Duane; Michel B Aboutanos; Rao R Ivatury
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

7.  Epidemiological characteristics and post-exposure prophylaxis of human rabies in Chongqing, China, 2007-2016.

Authors:  Li Qi; Kun Su; Tao Shen; Wenge Tang; Bangzhong Xiao; Jiang Long; Han Zhao; Xi Chen; Yu Xia; Yu Xiong; Dayong Xiao; Liangui Feng; Qin Li
Journal:  BMC Infect Dis       Date:  2018-01-03       Impact factor: 3.090

8.  Perceptions and Practices of Mass Bat Exposure Events in the Setting of Rabies Among U.S. Public Health Agencies.

Authors:  C H Hsu; C M Brown; J M Murphy; M G Haskell; C Williams; K Feldman; K Mitchell; J D Blanton; B W Petersen; R M Wallace
Journal:  Zoonoses Public Health       Date:  2016-07-08       Impact factor: 2.702

9.  Vital Signs: Trends in Human Rabies Deaths and Exposures - United States, 1938-2018.

Authors:  Emily G Pieracci; Christine M Pearson; Ryan M Wallace; Jesse D Blanton; Erin R Whitehouse; Xiaoyue Ma; Kendra Stauffer; Richard B Chipman; Victoria Olson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-06-14       Impact factor: 17.586

Review 10.  A Systematic Review of Human Bat Rabies Virus Variant Cases: Evaluating Unprotected Physical Contact with Claws and Teeth in Support of Accurate Risk Assessments.

Authors:  Virginia M Dato; Enzo R Campagnolo; Jonah Long; Charles E Rupprecht
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.